Sesen Bio Inc.

NASDAQ:SESN  
2.67
+0.05 (+1.91%)
Products

Sesen Bio Says Will Be Participating In A Late-Cycle Meeting With U.S. FDA To Discuss BLA For Vicineum On June 1, 2021 In U.S.

Published: 03/30/2021 13:32 GMT
Sesen Bio Inc. (SESN) - Sesen Bio Inc - Will Be Participating in a Late-cycle Meeting With U.S. FDA to Discuss Bla for Vicineum on June 1, 2021 in U.S.sesen Bio Inc - Remains On-track for Potential Approval of Vicineum in Europe in Early 2022.
Sesen Bio - Qilu Pharma Anticipates Submission of Product Market Application for Vicineum in 2022 With Potential Approval in China Expected in 2023.
Sesen Bio Inc - Anticipates First Wave of Potential Country Approvals for Vicineum in Mena Region As Early As 2022.